USCB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
USCB is not a good buy right now for an impatient investor. The stock is trading below its key pivot (19.3) with mildly bearish momentum signals, while the latest quarter (2025/Q4) showed sharp YoY declines in revenue and earnings despite balance-sheet growth. I would hold off buying until price reclaims ~19.3 and momentum improves; at current levels it’s more of a “wait/hold” than an immediate-entry buy.
Price/levels: Post-market ~18.85, below the pivot (19.3) and closer to support S1 (18.156) than resistance R1 (20.444), implying overhead supply and limited immediate upside unless it regains 19.3. Momentum: MACD histogram is negative (-0.136) and still below zero (bearish), though contracting (downside pressure may be easing). RSI(6) ~45 is neutral-to-soft, not signaling a strong reversal. Trend: Converging moving averages suggests consolidation rather than a clean uptrend.
Intellectia Proprietary Trading Signals
Pattern-based outlook provided: Similar-pattern stats indicate an 80% chance of modest gains (+1.21% next day, +5.52% next week, +12.19% next month), but the current technical setup is still not a strong “buy-now” trigger since price remains below the pivot and MACD is negative.
Capital/Shareholder actions: $40M subordinated debt issuance and repurchase of ~2M shares can support per-share value and sentiment. Trading trends: Hedge funds and insiders are neutral (no negative signal from positioning data provided). Congress trading: No recent congress trading data available (no political selling overhang indicated).
and S2 (17.
if support breaks. Leverage/cost of capital: Subordinated debt issuance can be a longer-term drag if funding costs rise or credit performance weakens (even though proceeds supported buybacks).
Latest quarter: 2025/Q4. Reported financial snapshot shows a clear YoY slowdown: revenue fell to 18,029,000 (-21.56% YoY), net income fell to 1,363,000 (-80.26% YoY), and EPS fell to 0.07 (-79.41% YoY). Offsetting positives from the news summary include stronger assets/loan/deposit growth and higher tangible book value per share, but the income statement trend is currently negative and is the key issue for a buy-now decision.
No analyst rating changes or price target updates were provided in the data, so there is no visible recent Wall Street consensus trend to lean on. Pros (based on provided fundamentals/news): improving tangible book value per share, loan/deposit growth, and share repurchases. Cons: sharp YoY declines in revenue, net income, and EPS in 2025/Q4, which undermines near-term confidence without evidence of an earnings rebound.
